Sugi Predict

Sugi Predict / Compounds / SCHEMBL874712

SCHEMBL874712

SCHEMBL874712

COCCOc1cc2c(Cl)nc(-c3cccc(OCc4ccccc4)c3)nc2cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.45
▸ PDGFRA P16234 1/20 0.45
▸ WHR1 P49842 1/20 0.45
▸ KDR P35968 3/20 0.44
▸ CYP1A2 P05177 4/20 0.44
▸ CYP3A4 P08684 4/20 0.44
▸ CYP2D6 P10635 3/20 0.44
▸ TSHR P16473 3/20 0.44
▸ CYP2C19 P33261 3/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ NTSR1 P30989 3/20 0.44
▸ ELANE P08246 1/20 0.44
▸ CYP2C9 P11712 3/20 0.42
▸ USP2 O75604 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10222126 0.86 ENPP1 (0.45) PDGFRBPDGFRAWHR1KDRCYP1A2
SCHEMBL873980 0.80 GUSB (0.48) KDRCYP1A2ELANEEGFR
SCHEMBL1941739 0.78 PDGFRB (0.50) PDGFRBPDGFRAWHR1ELANELMNA
SCHEMBL874001 0.78 POLB (0.52) CYP1A2CYP3A4NTSR1CYP2C9LMNA
SCHEMBL20771102 0.77 WHR1 (0.71) PDGFRBPDGFRAWHR1CYP1A2CYP3A4
SCHEMBL29589069 0.77 WHR1 (0.71) PDGFRBPDGFRAWHR1CYP1A2CYP3A4
SCHEMBL5032778 0.77 DHPS (0.64) PDGFRBPDGFRAMAOBERN1DHPS
SCHEMBL20509231 0.76 ELANE (0.55) PDGFRBPDGFRAELANELMNAEGFR
SCHEMBL29384944 0.76 ELANE (0.55) PDGFRBPDGFRAELANELMNAEGFR
SCHEMBL1940198 0.76 ELANE (0.55) PDGFRBPDGFRAELANELMNAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-9440961-B2 Rho-kinase inhibitors and method of preparation SURFACE LOGIX, INC. (US) 2016-09-13 — — US disclosed
US-20120202793-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2012-08-09 — — US disclosed
US-20120202793-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2012-08-09 — — US disclosed
WO-2012040499-A2 METABOLIC INHIBITORS SURFACE LOGIX, INC. (US) 2012-03-29 — — WO disclosed
EP-2406236-A1 RHO KINASE INHIBITORS Surface Logix, Inc. (US) 2012-01-18 — — EP disclosed
WO-2010104851-A1 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2010-09-16 — — WO disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
EP-1865958-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS Surface Logix, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006105081-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 PDGFRB 2690/4885PDGFRA 2909/4885WHR1 4028/4885
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 PDGFRB 2690/4885PDGFRA 2909/4885WHR1 4028/4885
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 PDGFRB 2690/4885PDGFRA 2909/4885WHR1 4028/4885
US-20100144707-A1 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 PDGFRB 2690/4885PDGFRA 2909/4885WHR1 4028/4885
US-10570123-B2 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 PDGFRB 2690/4885PDGFRA 2909/4885WHR1 4028/4885
US-20120202793-A1 RHO KINASE INHIBITORS ROCK2, ROCK1, RHOA PDGFRB 2378/4885PDGFRA 2737/4885WHR1 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.